{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:44:11Z","timestamp":1791607451226,"version":"4.3.4"},"reference-count":95,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022344","name":"Inflarx","doi-asserted-by":"crossref","award":["16LW0113"],"award-info":[{"award-number":["16LW0113"]}],"id":[{"id":"10.13039\/501100022344","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["IJMS"],"abstract":"<jats:p>Vilobelimab, a first-in-class, human\u2013mouse chimeric immunoglobulin G4 (IgG4) kappa monoclonal antibody, targets human complement component 5a (C5a) in plasma. Unlike upstream complement inhibitors, vilobelimab does not inhibit the generation of the membrane attack complex (C5b-9), necessary to mitigate certain infections. C5a is a strong anaphylatoxin and chemotactic agent that plays an essential role in both innate and adaptive immunity. Elevated levels of C5a have been associated with pathologic processes, including sepsis and inflammatory respiratory disorders such as acute respiratory distress syndrome (ARDS). Blocking C5a with vilobelimab has shown therapeutic promise. A randomized, multicenter placebo-controlled Phase III study of vilobelimab in patients with severe COVID-19 (PANAMO) found that patients treated with vilobelimab had a significantly lower risk of death by day 28 and 60. Based on this study, the United States Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Gohibic\u00ae (vilobelimab) injection for the treatment of COVID-19 in hospitalized adults when initiated within 48 h of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). In January 2025, the European Commission (EC) granted marketing authorization for Gohibic\u00ae (vilobelimab) for the treatment of adult patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced ARDS who are receiving systemic corticosteroids as part of standard of care and receiving IMV with or without ECMO. Herein, we review the mechanism of action of vilobelimab in selectively inhibiting C5a-induced inflammation, outlining its bench-to-bedside development from the fundamental biology of the complement system and preclinical evidence through to the clinical data demonstrating its life-saving potential in the management of COVID-19\u2013induced ARDS.<\/jats:p>","DOI":"10.3390\/ijms26199628","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:38:08Z","timestamp":1759397888000},"page":"9628","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Targeted Blockade of Terminal C5a Is Critical to Management of Sepsis and Acute Respiratory Distress Syndrome: The Mechanism of Action of Vilobelimab"],"prefix":"10.3390","volume":"26","author":[{"given":"Matthew W.","family":"McCarthy","sequence":"first","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Chong","sequence":"additional","affiliation":[{"name":"InflaRx GmbH, 07745 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels C.","family":"Riedemann","sequence":"additional","affiliation":[{"name":"InflaRx GmbH, 07745 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfeng","family":"Guo","sequence":"additional","affiliation":[{"name":"InflaRx Pharmaceuticals, Ann Arbor, MI 48103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/SQB.1989.054.01.003","article-title":"Approaching the asymptote? Evolution and revolution in immunology","volume":"54","author":"Janeway","year":"1989","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"ref_2","unstructured":"Janeway, C.A., Travers, P., and Walport, M. (2001). Principles of innate and adaptive immunity. Immunobiology: The Immune System in Health and Disease, Garland Science. [5th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"EVIDra2200118","DOI":"10.1056\/EVIDra2200118","article-title":"Immune Modulation in Sepsis, ARDS, and COVID-19\u2014The Road Traveled and the Road Ahead","volume":"1","author":"Leligdowicz","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.12703\/r\/9-25","article-title":"Phagocytosis and neutrophil extracellular traps","volume":"9","author":"DeLeo","year":"2020","journal-title":"Fac. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaad.2006.07.016","article-title":"From acute febrile neutrophilic dermatosis to neutrophilic disease: Forty years of clinical research","volume":"55","author":"Wallach","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: Analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ccc.2021.05.001","article-title":"The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019","volume":"37","author":"Hendrickson","year":"2021","journal-title":"Crit. Care Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0039-1683884","article-title":"Definitions, Epidemiology, Clinical Risk Factors, and Health Disparities in Acute Respiratory Distress Syndrome","volume":"40","author":"Kang","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_11","unstructured":"Diamond, M., Peniston, H.L., Sanghavi, D.K., and Mahapatra, S. (2024). Acute Respiratory Distress Syndrome, StatPearls."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40560-025-00781-3","article-title":"Epidemiological trends of mechanically ventilated acute respiratory distress syndrome in the twenty-first century: A nationwide, population-based retrospective study","volume":"13","author":"Aguilar","year":"2025","journal-title":"J. Intensive Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1378\/chest.07-2134","article-title":"Mortality rates for patients with acute lung injury\/ARDS have decreased over time","volume":"133","author":"Zambon","year":"2008","journal-title":"Chest"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1385\/IR:33:2:103","article-title":"The role of the complement system in innate immunity","volume":"33","author":"Rus","year":"2005","journal-title":"Immunol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"Sarma","year":"2011","journal-title":"Cell Tissue Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1124\/pr.111.005223","article-title":"International Union of Basic and Clinical Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors","volume":"65","author":"Klos","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clim.2017.03.012","article-title":"Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition","volume":"180","author":"Riedemann","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2350814","DOI":"10.1002\/eji.202350814","article-title":"The complement system: A key player in the host response to infections","volume":"54","author":"Jayaraman","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-025-02127-9","article-title":"Advances in acute respiratory distress syndrome: Focusing on heterogeneity, pathophysiology, and therapeutic strategies","volume":"10","author":"Ma","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"111930","DOI":"10.1016\/j.isci.2025.111930","article-title":"Complement is primarily activated in the lung in a mouse model of severe COVID-19","volume":"28","author":"Szachowicz","year":"2025","journal-title":"iScience"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.shk.0000105502.75189.5e","article-title":"Role of C5a-C5aR interaction in sepsis","volume":"21","author":"Guo","year":"2004","journal-title":"Shock"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40635-023-00520-8","article-title":"Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: A phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients","volume":"11","author":"Lim","year":"2023","journal-title":"Intensive Care Med. Exp."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/cts.13213","article-title":"The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19","volume":"15","author":"Vlaar","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","article-title":"Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"10","author":"Vlaar","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjd.18877","article-title":"Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: An open-label single-arm trial in patients not eligible for adalimumab","volume":"183","author":"Argyropoulou","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_27","first-page":"1054","article-title":"A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis","volume":"74","author":"Merkel","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2353\/ajpath.2007.070166","article-title":"The role of complement in inflammatory diseases from behind the scenes into the spotlight","volume":"171","author":"Markiewski","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1038\/ncomms10587","article-title":"Structural basis of complement membrane attack complex formation","volume":"7","author":"Serna","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev.iy.12.040194.004015","article-title":"C5A anaphylatoxin and its seven transmembrane-segment receptor","volume":"12","author":"Gerard","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.tibs.2020.04.004","article-title":"Emerging Insights into the Structure and Function of Complement C5a Receptors","volume":"45","author":"Pandey","year":"2020","journal-title":"Trends Biochem. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.4049\/jimmunol.1900371","article-title":"The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity","volume":"202","author":"Li","year":"2019","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Seiler, D.L., Kahler, K.H., Kleingarn, M., Sadik, C.D., Bieber, K., Kohl, J., Ludwig, R.J., and Karsten, C.M. (2023). The complement receptor C5aR2 regulates neutrophil activation and function contributing to neutrophil-driven epidermolysis bullosa acquisita. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1197709"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.bi.57.070188.001541","article-title":"Molecular organization and function of the complement system","volume":"57","year":"1988","journal-title":"Annu. Rev. Biochem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1172\/JCI141374","article-title":"Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis","volume":"130","author":"Skendros","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2009.10.007","article-title":"Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a","volume":"128","author":"Ali","year":"2010","journal-title":"Immunol. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1182\/bloodadvances.2021005246","article-title":"C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19","volume":"6","author":"Aiello","year":"2022","journal-title":"Blood Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/eji.201040355","article-title":"Complement fragments C3a and C5a: The salt and pepper of the immune response","volume":"40","author":"Sacks","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"C1731","DOI":"10.1152\/ajpcell.00213.2011","article-title":"Human colonic epithelial cells detect and respond to C5a via apically expressed C5aR through the ERK pathway","volume":"302","author":"Cao","year":"2012","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00281-011-0280-x","article-title":"Interactions between coagulation and complement\u2014Their role in inflammation","volume":"34","author":"Oikonomopoulou","year":"2012","journal-title":"Semin. Immunopathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI10793","article-title":"Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis","volume":"106","author":"Guo","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.1092385","article-title":"Neutrophil extracellular traps kill bacteria","volume":"303","author":"Brinkmann","year":"2004","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1702590","DOI":"10.1183\/13993003.02590-2017","article-title":"Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS","volume":"52","author":"Uhel","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhou, X., Jin, J., Lv, T., and Song, Y. (2024). A Narrative Review: The Role of NETs in Acute Respiratory Distress Syndrome\/Acute Lung Injury. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031464"},{"key":"ref_45","first-page":"651","article-title":"Activation of the complement system in the adult respiratory distress syndrome","volume":"135","author":"Robbins","year":"1987","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1128\/iai.61.10.4293-4301.1993","article-title":"Activation of the complement system in baboons challenged with live Escherichia coli: Correlation with mortality and evidence for a biphasic activation pattern","volume":"61","author":"Creasey","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_47","first-page":"489","article-title":"Endotoxin-induced shock in the rat. A role for C5a","volume":"135","author":"Cui","year":"1989","journal-title":"Am. J. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.4049\/jimmunol.1002741","article-title":"Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis","volume":"186","author":"Dahlke","year":"2011","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1128\/IAI.72.9.5247-5252.2004","article-title":"Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis","volume":"72","author":"Windbichler","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: A new complement activation pathway","volume":"12","author":"Sarma","year":"2006","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1172\/JCI112506","article-title":"Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates","volume":"77","author":"Stevens","year":"1986","journal-title":"J. Clin. Investig."},{"key":"ref_52","first-page":"396","article-title":"Adult respiratory distress syndrome. A live E coli septic primate model","volume":"126","author":"Hangen","year":"1987","journal-title":"Am. J. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E6390","DOI":"10.1073\/pnas.1706818114","article-title":"Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis","volume":"114","author":"Keshari","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nprot.2008.214","article-title":"Immunodesign of experimental sepsis by cecal ligation and puncture","volume":"4","author":"Rittirsch","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00024382-199801000-00001","article-title":"Animal models of sepsis and shock: A review and lessons learned","volume":"9","author":"Deitch","year":"1998","journal-title":"Shock"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1096\/fj.03-0009fje","article-title":"Neutrophil C5a receptor and the outcome in a rat model of sepsis","volume":"17","author":"Guo","year":"2003","journal-title":"FASEB J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/00365540310015674","article-title":"Anti-complement strategies in experimental sepsis","volume":"35","author":"Ward","year":"2003","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/10512","article-title":"Protective effects of C5a blockade in sepsis","volume":"5","author":"Czermak","year":"1999","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.4049\/jimmunol.166.2.1193","article-title":"Role of C5a in multiorgan failure during sepsis","volume":"166","author":"Sarma","year":"2001","journal-title":"J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1172\/JCI0215409","article-title":"Increased C5a receptor expression in sepsis","volume":"110","author":"Riedemann","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1084\/jem.20072248","article-title":"C5 deficiency and C5a or C5aR blockade protects against cerebral malaria","volume":"205","author":"Patel","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41426-018-0063-8","article-title":"Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV","volume":"7","author":"Jiang","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(80)91403-8","article-title":"Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value","volume":"1","author":"Hammerschmidt","year":"1980","journal-title":"Lancet"},{"key":"ref_64","first-page":"1058","article-title":"Complement activation in patients at risk of developing the adult respiratory distress syndrome","volume":"130","author":"Duchateau","year":"1984","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41586-020-2600-6","article-title":"Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis","volume":"588","author":"Carvelli","year":"2020","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/archsurg.1988.01400290131023","article-title":"Anaphylatoxin formation in sepsis","volume":"123","author":"Bengtson","year":"1988","journal-title":"Arch. Surg."},{"key":"ref_67","first-page":"189","article-title":"Serum complement levels and severity of sepsis","volume":"84","author":"Nakae","year":"1994","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1164\/ajrccm\/138.2.368","article-title":"Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome","volume":"138","author":"Langlois","year":"1988","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood-2003-03-0703","article-title":"Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis","volume":"102","author":"Sprong","year":"2003","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/cei.13166","article-title":"Blood clotting and traumatic injury with shock mediates complement-dependent neutrophil priming for extracellular ROS, ROS-dependent organ injury and coagulopathy","volume":"194","author":"Barrett","year":"2018","journal-title":"Clin. Exp. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e163105","DOI":"10.1172\/JCI163105","article-title":"C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps","volume":"133","author":"Silva","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1182\/blood.2020007008","article-title":"Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome","volume":"136","author":"Middleton","year":"2020","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s10875-021-01061-z","article-title":"Elevated Expression Levels of Lung Complement Anaphylatoxin, Neutrophil Chemoattractant Chemokine IL-8, and RANTES in MERS-CoV-Infected Patients: Predictive Biomarkers for Disease Severity and Mortality","volume":"41","author":"Hamed","year":"2021","journal-title":"J. Clin. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"100590","DOI":"10.1016\/j.eclinm.2020.100590","article-title":"Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study","volume":"28","author":"Annane","year":"2020","journal-title":"eClinicalMedicine"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Raghunandan, S., Josephson, C.D., Verkerke, H., Linam, W.M., Ingram, T.C., Zerra, P.E., Arthur, C.M., Stowell, S.R., Briones, M., and Chonat, S. (2020). Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome. Front. Pediatr., 8.","DOI":"10.3389\/fped.2020.616731"},{"key":"ref_76","first-page":"4040","article-title":"Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience","volume":"24","author":"Diurno","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S2213-2600(23)00082-6","article-title":"Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: A phase 3, multicentre, open-label, randomised controlled trial","volume":"11","author":"Annane","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S2213-2600(23)00376-4","article-title":"Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): A randomised, parallel-arm, open-label, phase 4 trial","volume":"11","author":"Hall","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_79","unstructured":"Apellis (2025, June 30). Apellis Initiates Phase 1\/2 Study of APL-9 in Patients with Severe COVID-19. Available online: https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-provides-update-apl-9-severe-covid-19."},{"key":"ref_80","first-page":"e0577","article-title":"Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)","volume":"3","author":"Bauer","year":"2021","journal-title":"Crit. Care Explor."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1016\/S2665-9913(20)30341-6","article-title":"Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): An exploratory, open-label, phase 2 randomised controlled trial","volume":"2","author":"Vlaar","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1165\/rcmb.2012-0428OC","article-title":"Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection","volume":"49","author":"Sun","year":"2013","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/ciu887","article-title":"Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys","volume":"60","author":"Sun","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1097\/CCM.0000000000002950","article-title":"Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application","volume":"46","author":"Sun","year":"2018","journal-title":"Crit. Care Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Carlini, V., Noonan, D.M., Abdalalem, E., Goletti, D., Sansone, C., Calabrone, L., and Albini, A. (2023). The multifaceted nature of IL-10: Regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1161067"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1186\/s13063-024-08679-5","article-title":"Limitation of site-stratified cox regression analysis in survival data: A cautionary tale of the PANAMO phase III randomized, controlled study in critically ill COVID-19 patients","volume":"25","author":"Sandrock","year":"2024","journal-title":"Trials"},{"key":"ref_87","unstructured":"FDA, U.S. (2025, June 30). Emergency Use Authorization (EUA) Summary Review for Gohibic (Vilobelimab), Available online: https:\/\/www.fda.gov\/media\/167044\/download."},{"key":"ref_88","unstructured":"EMA (2025). Authorization of Gohibic (Vilobelimab), The Committee for Medicinal Products for Human Use (CHMP). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gohibic-epar-product-information_en.pdf."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"A2225","DOI":"10.1016\/j.chest.2024.06.1369","article-title":"Vilobelimab in combination with tocilizumab may synergistically improve mortality in critically ill COVID-19 patients: A post-hoc analysis of the phase III PANAMO study","volume":"166","author":"Sandrock","year":"2024","journal-title":"CHEST"},{"key":"ref_90","first-page":"A5511","article-title":"Vilobelimab in Combination With Tocilizumab or Baricitinib Dramatically Improves Mortality in Critically Ill COVID-19 Patients: A Subgroup Analysis","volume":"209","author":"Shorr","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Chemaly, R.F., Vlaar, A., Lim, E.H.T., Burnett, B.P., Chong, C., R\u00fcckinger, s., Zerbib, R., Panas, R.M., Guo, R., and Riedemann, N. (Open Forum Infect. Dis., 2025). 85. Improved Survival with Dual Immunomodulator Treatment of ARDS by blocking C5a and IL-6 Activity: Subanalysis from the PANAMO Study in Critically Ill COVID-19 Patients, Open Forum Infect. Dis.","DOI":"10.1093\/ofid\/ofae631.022"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1096\/fj.03-0708fje","article-title":"Regulatory role of C5a in LPS-induced IL-6 production by neutrophils during sepsis","volume":"18","author":"Riedemann","year":"2004","journal-title":"FASEB J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4049\/jimmunol.170.1.503","article-title":"Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression","volume":"170","author":"Riedemann","year":"2003","journal-title":"J. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/jcmm.16157","article-title":"Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut-kidney axis","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7607","DOI":"10.2147\/CMAR.S326352","article-title":"By Increasing the Expression and Activation of STAT3, Sustained C5a Stimulation Increases the Proliferation, Migration, and Invasion of RCC Cells and Promotes the Growth of Transgrafted Tumors","volume":"13","author":"Zheng","year":"2021","journal-title":"Cancer Manag. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9628\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:22:42Z","timestamp":1759551762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/19\/9628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":95,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26199628"],"URL":"https:\/\/doi.org\/10.3390\/ijms26199628","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}